title: Alemtuzumab-induced remission of multiple sclerosis-associated uveitis.
abstract: OBJECTIVE
  The purpose of the study was to report a case of multiple sclerosis (MS)-associated uveitis refractory to conventional immunosuppressants, with subsequent remission following treatment with alemtuzumab.
  
  
  METHODS
  Case report Patient was treated with intravenous alemtuzumab, a lymphocyte depleting anti-CD52 monoclonal antibody that has recently been approved for use in relapsing MS.
  
  
  RESULTS
  A 17-year-old female presented with bilateral optic neuritis and subsequently bilateral intermediate uveitis and secondary macular oedema. She was diagnosed with active relapsing MS for which she received treatment with alemtuzumab. The intraocular inflammation previously refractory to conventional immunosuppressants responded to alemtuzumab, inducing remission.
  
  
  CONCLUSIONS
  To our knowledge, this is the first such report of alemtuzumab treatment in MS-associated ocular inflammatory disease and may demonstrate a potential utility for this drug in related conditions.
authors.affiliation: Institute of Psychological Medicine and Clinical Neuroscience, Cardiff University, University Hospital of Wales, Heath Park, Cardiff, CF14 4XN, UK.|Department of Neurology, University Hospital of Wales, Heath Park, Cardiff, UK.
authors.forename: Mark D
authors.initials: MD
authors.lastname: Willis
authors.affiliation: Department of Neurology, University Hospital of Wales, Heath Park, Cardiff, UK.
authors.forename: Trevor P
authors.initials: TP
authors.lastname: Pickersgill
authors.affiliation: Institute of Psychological Medicine and Clinical Neuroscience, Cardiff University, University Hospital of Wales, Heath Park, Cardiff, CF14 4XN, UK.|Department of Neurology, University Hospital of Wales, Heath Park, Cardiff, UK.
authors.forename: Neil P
authors.initials: NP
authors.lastname: Robertson
authors.affiliation: Bristol Eye Hospital, University Hospitals Bristol NHS Foundation Trust, Lower Maudlin Street, Bristol, UK.|School of Clinical Sciences, Faculty of Health Sciences, University of Bristol, Bristol, UK.|National Institute for Health Research Biomedical Research Centre, Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London, UK.
authors.forename: Richard W J
authors.initials: RWJ
authors.lastname: Lee
authors.affiliation: Bristol Eye Hospital, University Hospitals Bristol NHS Foundation Trust, Lower Maudlin Street, Bristol, UK.|School of Clinical Sciences, Faculty of Health Sciences, University of Bristol, Bristol, UK.|National Institute for Health Research Biomedical Research Centre, Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London, UK.
authors.forename: Andrew D
authors.initials: AD
authors.lastname: Dick
authors.affiliation: Bristol Eye Hospital, University Hospitals Bristol NHS Foundation Trust, Lower Maudlin Street, Bristol, UK. carregnito@gmail.com.
authors.forename: Ester
authors.identifier: http://orcid.org/0000-0002-0055-9547
authors.initials: E
authors.lastname: Carreño
mesh_terms: D000293:Adolescent; D000074323:Alemtuzumab / Q000008:administration & dosage*; D000074322:Antineoplastic Agents, Immunological / Q000008:administration & dosage; D001921:Brain / Q000000981:diagnostic imaging; D004305:Dose-Response Relationship, Drug; D005260:Female; D005451:Fluorescein Angiography; D005654:Fundus Oculi; D006801:Humans; D008279:Magnetic Resonance Imaging; D009103:Multiple Sclerosis / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy; D012074:Remission Induction; D041623:Tomography, Optical Coherence; D014605:Uveitis / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology
chemical_list: D000074322:Antineoplastic Agents, Immunological; D000074323:Alemtuzumab
keywords: Alemtuzumab; Intraocular inflammation; Multiple sclerosis; Uveitis